-
Uncategorized1 month agoSTAT+: Trump pivots on kratom derivative 7-OH, floating approval for some forms
President Trump on Monday suggested the federal government could move to approve some forms of 7-OH, an opioid derived from the naturally occurring kratom plant. “We’re...
-
Uncategorized1 month agoNo FDA permission, no problem: New flavored vape policy worries experts
The tobacco industry chalked up another win on Friday with a new policy announced by the Food and Drug Administration that gives what one expert called...
-
Uncategorized1 month agoCongress extends Rare Pediatric Disease Priority Review Voucher programme through 2029
Brian Malkin and Sadaf Deedar, Spencer Fane LLP, unpack the recent changes to the FDA’s Priority Review Voucher scheme and the upcoming review of its effectiveness...
-
Uncategorized1 month agoGSK cuts deal with Sino to broaden reach of hepatitis B drug
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called...
-
Uncategorized1 month ago
Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new...
-
Uncategorized1 month ago
New home for Novo’s Parkinson’s cell therapy; GSK turns to China for hep B drug
Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial: 🧠 Novo’s Parkinson’s cell therapy finds a biotech home:...
-
Uncategorized1 month ago
RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer
In a new study published in Cell titled, “RegVelo: gene-regulatory-informed dynamics of single cells,” researchers from Stowers Institute of Medical Research have developed a new AI model that connects...
-
Uncategorized1 month agoSTAT+: Astellas treatment offers new hope to a devastated rare disease community
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. There’s fresh turmoil at the...
-
Uncategorized1 month ago
Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win
Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition...
-
Uncategorized1 month ago
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
While Daiichi Sankyo brought in $13.4 billion in 2025, setbacks forced the company to update its antibody-drug conjugate forecast, pushing demand below the minimum supply agreed...
